{"id":7779,"date":"2024-11-18T10:58:36","date_gmt":"2024-11-18T02:58:36","guid":{"rendered":"https:\/\/regask.com\/?p=7779"},"modified":"2024-11-21T17:44:39","modified_gmt":"2024-11-21T09:44:39","slug":"japan-mhlw-fordert-rwd-pharma-zulassungen","status":"publish","type":"post","link":"https:\/\/regask.com\/de\/japan-mhlw-promotes-rwd-pharma-approvals\/","title":{"rendered":"MHLW (Japan) f\u00f6rdert die Verwendung von Real-World-Daten (RWD) f\u00fcr \u2026"},"content":{"rendered":"<p>Am 7. Oktober 2024 ver\u00f6ffentlichte das japanische Ministerium f\u00fcr Gesundheit, Arbeit und Soziales (MHLW) eine wichtige Mitteilung, in der die Nutzung von Real-World-Daten (RWD) zur Unterst\u00fctzung partieller \u00c4nderungen bei Arzneimittelzulassungen gef\u00f6rdert wird. Diese Aktualisierung, die in einem Artikel von Pharma Japan hervorgehoben wird, stellt einen strategischen Schritt zur Nutzung von Patientenregisterdaten \u2013 die Krankheitsprofile, Behandlungsdetails und Nachbeobachtungsergebnisse abdecken \u2013 als glaubw\u00fcrdige Alternative zu herk\u00f6mmlichen klinischen Studien f\u00fcr bestimmte regulatorische \u00c4nderungen dar. Die Initiative unterstreicht das Engagement des MHLW, Real-World-Evidenz in regulatorische Entscheidungen einzubeziehen und so letztlich Innovationen im Gesundheitswesen und das Lebenszyklusmanagement f\u00fcr Arzneimittel zu verbessern.<\/p>\n<p><strong>Kernpunkte der Mitteilung<\/strong><\/p>\n<p>Die Mitteilung richtet sich an Pharmaunternehmen, die \u00c4nderungen an Produktzulassungen w\u00fcnschen, f\u00fcr die keine umfassenden klinischen Studien erforderlich sind. Diese \u00c4nderungen k\u00f6nnen Anpassungen in folgenden Bereichen umfassen:<\/p>\n<ul>\n<li><strong>Indikationen<\/strong>: Erweiterung oder Spezifizierung therapeutischer Anwendungen.<\/li>\n<li><strong>Dosierungen<\/strong>: \u00c4nderungen der empfohlenen Dosierung.<\/li>\n<li><strong>Weitere wichtige Aspekte<\/strong>: Verschiedene wesentliche \u00c4nderungen, wie von MHLW definiert.<\/li>\n<\/ul>\n<p>RWD umfasst Daten aus Quellen wie elektronischen Gesundheitsakten (EHRs), Krankheits- und Produktregistern, von Patienten berichteten Ergebnissen und Daten aus der h\u00e4uslichen Anwendung und liefert wertvolle Erkenntnisse aus tats\u00e4chlichen klinischen Umgebungen und stellt eine praktische Erg\u00e4nzung zu traditionellen klinischen Studien dar.<\/p>\n<p><strong>Umfang und Empfehlungen<\/strong><\/p>\n<p>Obwohl die Therapiebereiche oder Produktkategorien nicht konkret definiert sind, deutet die Mitteilung darauf hin, dass die Richtlinie f\u00fcr ein breites Spektrum pharmazeutischer und medizinischer Produkte gelten k\u00f6nnte. Unternehmen, die RWD f\u00fcr Zulassungsantr\u00e4ge in Betracht ziehen, wird empfohlen, sich fr\u00fchzeitig mit dem MHLW in Verbindung zu setzen, um sicherzustellen, dass ihre Daten den MHLW-Standards hinsichtlich Qualit\u00e4t, Relevanz und Zuverl\u00e4ssigkeit entsprechen.<\/p>\n<p><strong>Abschluss<\/strong><\/p>\n<p>Diese MHLW-Initiative ermutigt japanische Pharmaunternehmen, RWD als valide regulatorische Ressource zu nutzen und effiziente, datenbasierte Anpassungen bei Produktzulassungen zu f\u00f6rdern. Da Japan weiterhin auf Real-World-Evidenz im Gesundheitswesen setzt, wird dieser Ansatz die <a href=\"https:\/\/regask.com\/de\/registrierung-kosmetischer-inhaltsstoffe-in-japan\/\">Regulierungsweg<\/a> f\u00fcr innovative Behandlungen und gew\u00e4hrleistet so einen rechtzeitigen Zugang zu verbesserten Therapien.<\/p>\n<hr \/>","protected":false},"excerpt":{"rendered":"<p>Am 7. Oktober 2024 ver\u00f6ffentlichte das japanische Ministerium f\u00fcr Gesundheit, Arbeit und Soziales (MHLW) eine wichtige Mitteilung, die die Nutzung von Real-World-Daten (RWD) zur Unterst\u00fctzung von Teil\u00e4nderungen bei der Zulassung von Arzneimitteln f\u00f6rdert. Diese Aktualisierung, die in einem Artikel von Pharma Japan hervorgehoben wurde, stellt einen strategischen Schritt hin zur Nutzung von Patientenregisterdaten dar \u2013 einschlie\u00dflich Krankheitsprofilen, Behandlungsdetails und Nachsorgeinformationen.<\/p>","protected":false},"author":43,"featured_media":7847,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[35,519],"tags":[387,496],"class_list":["post-7779","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-biotech-latest-insights","category-japan-regulations","tag-real-word-evidence-rwe","tag-market-authorization-regs"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.5 (Yoast SEO v28.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Japan MHLW Promotes RWD for Pharma Approvals | RegASK<\/title>\n<meta name=\"description\" content=\"Japan\u2019s MHLW encourages use of real-world data for pharma approval, boosting innovation. Read more at RegASK.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/de\/japan-mhlw-fordert-rwd-pharma-zulassungen\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MHLW (Japan) Encourages Use of Real-World Data (RWD) for Modifications in Pharmaceutical Approvals\" \/>\n<meta property=\"og:description\" content=\"Japan\u2019s MHLW encourages use of real-world data for pharma approval, boosting innovation. Read more at RegASK.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/de\/japan-mhlw-fordert-rwd-pharma-zulassungen\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-18T02:58:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-21T09:44:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2024\/11\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"MHLW (Japan) Encourages Use of Real-World Data (RWD) fo&hellip;\",\"datePublished\":\"2024-11-18T02:58:36+00:00\",\"dateModified\":\"2024-11-21T09:44:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/\"},\"wordCount\":299,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png\",\"keywords\":[\"Real-Word-Evidence (RWE)\",\"Market authorization regs\"],\"articleSection\":[\"Pharma and Biotech\",\"Japan\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/\",\"name\":\"Japan MHLW Promotes RWD for Pharma Approvals | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png\",\"datePublished\":\"2024-11-18T02:58:36+00:00\",\"dateModified\":\"2024-11-21T09:44:39+00:00\",\"description\":\"Japan\u2019s MHLW encourages use of real-world data for pharma approval, boosting innovation. Read more at RegASK.\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png\",\"width\":800,\"height\":600,\"caption\":\"Mhlw Japan Encourages Use Real World Data Rwd Modifications Pharmaceutical Approvals\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@RegASK\",\"https:\\\/\\\/www.crunchbase.com\\\/organization\\\/regask\",\"https:\\\/\\\/www.bloomberg.com\\\/profile\\\/company\\\/1691237D:SP\",\"https:\\\/\\\/pitchbook.com\\\/profiles\\\/company\\\/265004-02\",\"https:\\\/\\\/www.cbinsights.com\\\/company\\\/RegASK\",\"https:\\\/\\\/vimeo.com\\\/RegASK\"],\"legalName\":\"RegASK PTE. LTD.\",\"foundingDate\":\"2018\",\"slogan\":\"Empowering Smarter Regulatory Decisions\",\"description\":\"Agentic AI regulatory intelligence and workflow orchestration platform for Life Sciences and Consumer Products. RegASK combines vertical LLMs, multi-agent AI architecture, and a global community of 1,800+ subject matter experts to deliver regulatory horizon scanning, impact analysis, compliance workflow automation, and audit-ready outputs across 160+ countries.\",\"areaServed\":\"Worldwide\",\"founder\":{\"@type\":\"Person\",\"name\":\"Caroline Shleifer\",\"jobTitle\":\"Founder & CEO\"},\"address\":{\"@type\":\"PostalAddress\",\"streetAddress\":\"79 Science Park Drive, #06-01, Cintech IV\",\"addressLocality\":\"Singapore\",\"postalCode\":\"118264\",\"addressCountry\":\"SG\"},\"contactPoint\":{\"@type\":\"ContactPoint\",\"telephone\":\"+65 6817 6290\",\"contactType\":\"customer service\",\"availableLanguage\":[\"English\",\"French\",\"Japanese\",\"Spanish\",\"Chinese\",\"German\"]},\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":50,\"maxValue\":100},\"knowsAbout\":[\"Regulatory Intelligence\",\"Regulatory Compliance\",\"Regulatory Affairs\",\"Workflow Orchestration\",\"Life Sciences Regulation\",\"Consumer Products Regulation\",\"AI-Driven Compliance\"],\"hasCertification\":[{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 42001:2023\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27001:2022\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27701\"},{\"@type\":\"Certification\",\"name\":\"ISO\\\/IEC 27018:2019\"},{\"@type\":\"Certification\",\"name\":\"SOC 2 Type II\"}]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Japan MHLW f\u00f6rdert RWD f\u00fcr Pharmazulassungen | RegASK","description":"Das japanische MHLW f\u00f6rdert die Nutzung realer Daten f\u00fcr die Arzneimittelzulassung und f\u00f6rdert so Innovationen. Lesen Sie mehr unter RegASK.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/de\/japan-mhlw-fordert-rwd-pharma-zulassungen\/","og_locale":"de_DE","og_type":"article","og_title":"MHLW (Japan) Encourages Use of Real-World Data (RWD) for Modifications in Pharmaceutical Approvals","og_description":"Japan\u2019s MHLW encourages use of real-world data for pharma approval, boosting innovation. Read more at RegASK.","og_url":"https:\/\/regask.com\/de\/japan-mhlw-fordert-rwd-pharma-zulassungen\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2024-11-18T02:58:36+00:00","article_modified_time":"2024-11-21T09:44:39+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/11\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Reva Ananda","Est. reading time":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/#article","isPartOf":{"@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"MHLW (Japan) Encourages Use of Real-World Data (RWD) fo&hellip;","datePublished":"2024-11-18T02:58:36+00:00","dateModified":"2024-11-21T09:44:39+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/"},"wordCount":299,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/11\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png","keywords":["Real-Word-Evidence (RWE)","Market authorization regs"],"articleSection":["Pharma and Biotech","Japan"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/","url":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/","name":"Japan MHLW f\u00f6rdert RWD f\u00fcr Pharmazulassungen | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/11\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png","datePublished":"2024-11-18T02:58:36+00:00","dateModified":"2024-11-21T09:44:39+00:00","description":"Das japanische MHLW f\u00f6rdert die Nutzung realer Daten f\u00fcr die Arzneimittelzulassung und f\u00f6rdert so Innovationen. Lesen Sie mehr unter RegASK.","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/11\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/11\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png","width":800,"height":600,"caption":"Mhlw Japan Encourages Use Real World Data Rwd Modifications Pharmaceutical Approvals"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Das regulatorische KI-Betriebssystem f\u00fcr leistungsstarke Teams","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/@RegASK","https:\/\/www.crunchbase.com\/organization\/regask","https:\/\/www.bloomberg.com\/profile\/company\/1691237D:SP","https:\/\/pitchbook.com\/profiles\/company\/265004-02","https:\/\/www.cbinsights.com\/company\/RegASK","https:\/\/vimeo.com\/RegASK"],"legalName":"RegASK PTE. LTD.","foundingDate":"2018","slogan":"Empowering Smarter Regulatory Decisions","description":"Agentic AI ist eine Plattform f\u00fcr regulatorische Analysen und Workflow-Orchestrierung in den Bereichen Life Sciences und Konsumg\u00fcter. RegASK kombiniert vertikale LLMs, eine Multiagenten-KI-Architektur und eine globale Community von \u00fcber 1.800 Fachexperten, um regulatorische Zukunftsprognosen, Wirkungsanalysen, die Automatisierung von Compliance-Workflows und auditfertige Ergebnisse in \u00fcber 160 L\u00e4ndern bereitzustellen.","areaServed":"Worldwide","founder":{"@type":"Person","name":"Caroline Shleifer","jobTitle":"Founder & CEO"},"address":{"@type":"PostalAddress","streetAddress":"79 Science Park Drive, #06-01, Cintech IV","addressLocality":"Singapore","postalCode":"118264","addressCountry":"SG"},"contactPoint":{"@type":"ContactPoint","telephone":"+65 6817 6290","contactType":"customer service","availableLanguage":["English","French","Japanese","Spanish","Chinese","German"]},"numberOfEmployees":{"@type":"QuantitativeValue","minValue":50,"maxValue":100},"knowsAbout":["Regulatory Intelligence","Regulatory Compliance","Regulatory Affairs","Workflow Orchestration","Life Sciences Regulation","Consumer Products Regulation","AI-Driven Compliance"],"hasCertification":[{"@type":"Certification","name":"ISO\/IEC 42001:2023"},{"@type":"Certification","name":"ISO\/IEC 27001:2022"},{"@type":"Certification","name":"ISO\/IEC 27701"},{"@type":"Certification","name":"ISO\/IEC 27018:2019"},{"@type":"Certification","name":"SOC 2 Type II"}]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"Reva Ananda"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/7779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/comments?post=7779"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/7779\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media\/7847"}],"wp:attachment":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media?parent=7779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/categories?post=7779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/tags?post=7779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}